When you think of women and cancer, the first type of cancer that comes to mind is most likely breast cancer and this is with good reason. 1 in 8 women will be diagnosed with breast cancer in her lifetime, and roughly 40,000 women die from breast cancer each year. This is tragic, and we need to do everything we can to prevent and treat the disease.
But did you know that breast cancer is not the deadliest cancer affecting women? It’s actually lung cancer. That’s right, according to Lynne Eldridge, MD, a physician and lung cancer expert, lung cancer kills “more women each year than breast cancer, uterine cancer, and ovarian cancer combined.”
Oncimmune (LON:ONC) is a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer. Oncimmune is changing how clinicians, researchers and patients view, diagnose and treat cancer. Our technology detects evidence of the body’s natural response to cancer, enabling detection 4 years or more before standard clinical diagnosis. Our tests facilitate clinical decision-making and are complementary to diagnostic technologies, making them valuable additions to established and new care pathways. We partner with leading developers and distributors to make our technology available globally.
